US EditionPublished • loading... • Updated
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
ASC37 shows 57-fold higher drug exposure than retatrutide and 4.2% oral bioavailability using POTENT technology, supporting its potential for chronic obesity treatment.
Summary by Charleston Gazette-Mail
9 Articles
9 Articles
Rutland Herald+8 Reposted by 8 other sources
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to-head non-human primate…
Coverage Details
Total News Sources9
Leaning Left2Leaning Right0Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
